DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

ZBH·Zimmer Biomet Holdings, Inc.

$.
+. (+.%)
After Hours
High
$91.94
Open
$89.69
Market Cap
17.61B
52W High
$108.29
Low
$89.23
P. Close
$91.36
P/E
23.15
52W Low
$79.12
Fwd P/E
10.16
DailyIQ Est.
$98.22
Technical Score (1D)
55
BUY
News Sentiment
59
BULLISH
BMO Capital’s 4.4‑hour‑old coverage launch signals a fresh institutional view, rating Zimmer Biomet Holdings (ZBH) as Market Perform after noting its recent earnings beat and steady revenue growth from an expanding orthopedic‑implant portfolio. The rating implies no immediate upside or downside catalyst, but it underscores the company’s solid fundamentals and the potential for incremental margin improvement as new knee‑joint and robotic‑surgery products roll out. ZBH’s year‑to‑date share decline of 0.8 % and its lag behind the broader medical‑instrument sector suggest that market sentiment remains cautious, especially as competitors like Stryker and Globus Medical also posted modest drops. The company’s focus on knee‑joint expansion and robotics integration is intended to offset competitive pressures and macro headwinds, but the pace of adoption in the U.S. and Europe will dictate near‑term earnings momentum. Regulatory approvals for its latest robotic‑surgery devices remain a key uncertainty; any delay could dampen the expected margin lift. The upcoming earnings release next week will provide guidance on robotics initiatives and the progress of its restructuring program, offering a clearer view of revenue and margin prospects. Traders should also monitor macro data on consumer spending and healthcare reimbursement trends, as these factors influence demand for elective orthopedic procedures. Finally, watch for any updates on the company’s regulatory filings and the competitive positioning of its new product lines, as these will shape the next 1–10 trading days’ outlook.
Earnings Summary
Zimmer Biomet Holdings is a global medical‑device company specializing in orthopedic and related surgical solutions, including knee and hip implants, sports‑medicine devices, and robotic‑assisted technologies, operating within the healthcare medical‑devices industry. The company’s recent earnings show a robust performance: Q4 2025 revenue reached $2.2438 billion, up from $2.0014 billion in Q3 2025 and $2.0773 billion in Q2 2025, while EPS surged to $2.42 from $1.90 in Q3 2025 and $2.07 in Q2 2025, with every quarter beating consensus estimates—Q4 2025 EPS of $2.42 versus an estimate of $1.908, and Q4 2024 EPS of $2.31 versus $2.293. Historically, Zimmer Biomet has exhibited a consistent streak of EPS beats and revenue growth, reflecting strong demand for its high‑tech orthopedic products and a resilient margin profile; the company’s recurring revenue from implant sales and the integration of new technologies have supported this trend. Recent news underscores strategic moves such as the acquisition of Pacira’s iovera device, which expands the company’s portfolio into spasticity neuromodulation, and the launch of BMO Capital coverage, which may increase analyst visibility; meanwhile, Evercore’s rating adjustment reflects concerns over margin pressure and cost control. Investors should watch for guidance on revenue growth, cost‑control initiatives, and the progress of iovera regulatory approvals, as well as any updates on the company’s expansion into robotic‑assisted procedures, since these factors will shape the next quarter’s earnings trajectory and margin outlook.

EPS

EstBeatMiss
$1.67$1.88$2.09$2.31$2.52Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$2.01 - -
Q4'25$1.91$2.42+26.8%
Q3'25$1.87$1.90+1.8%
Q2'25$1.98$2.07+4.8%
Q1'25$1.77$1.81+2.3%
Q4'24$2.29$2.31+0.8%

Revenue

EstBeatMiss
$1.9B$2.0B$2.1B$2.2B$2.3BQ4'24Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$2.1B - -
Q4'25$2.1B$2.2B+9.0%
Q3'25 - $2.0B -
Q2'25 - $2.1B -
Q1'25 - $1.9B -
Q4'24 - $2.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ZBH Stock Snapshot

ZBH is currently trading at $91.25, giving Zimmer Biomet Holdings, Inc. a market cap of 17.61B and a P/E ratio of 23.1. Today's range spans $89.23–$91.94, with shares opening at $89.69 and moving down $0.11 (0.1%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 59/100.

Over the past year ZBH has traded between $79.12 and $108.29 - the current price is +15.3% off the 52-week low and -15.7% from the high. 35 analysts cover the stock with a Hold consensus and a mean 12-month target of $98.05 (range $83.00–$130.00), implying upside of +7.5%.

Neutral technical setups in large-cap Healthcare names are inherently unstable - they resolve. Right now, ZBH (55/100, HOLD, price $91.25, in the lower half of its 52-week range) is waiting for that resolution. Sentiment: neutral at 59/100. The current P/E ratio stands at 23.1. With 17.61B in market cap, the 52-week range of $79.12–$108.29 is where structural support and resistance live - and which one holds when the next catalyst hits will define the next trade.

The 52-week range of $79.12–$108.29 for ZBH provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $91.25 (in the lower half of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 55/100 and neutral news backdrop (59/100) don't break the tie yet, but they narrow the probability distribution toward the upside.